drugset / Trial / NCT07064707
Rupatadine in Patients With Ulcerative Colitis
Phase 2
Recruiting
60 enrolled
Alexandria University
Assoc. Prof. Dr. Ibrahim Fathi Amer, Faculty of Medecine, Kafr Elsheikh University. · collabAssoc. Prof. Dr. Noha Alaa Eldin Hassan Hamdy, Faculty of pharmacy, Alexandria University. · collabProf. Dr. Ahmed Ibrahim Mohammed El Mallah, faculty of pharmacy, Alexandria University. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Ulcerative colitis (UC) is a chronic inflammatory condition that primarily targets the large intestine. Although substantial progress has been made in treatment modalities-especially with the development of immunomodulatory drugs and biologic therapies-managing UC continues to present significant challenges. At present, there is no definitive cure, and current treatment strategies are largely focused on controlling inflammation, relieving symptoms, and halting disease progression
Timeline
- Start
- 2025-07-15
- Primary completion
- 2026-07-15
- Completion
- 2026-10-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rupatadine | Small molecule | 20 mg | — |
| Comparator | Mesalamine | Small molecule | 1 g | — |